Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
One Percent Rule Checklist For Safer Forex Trading Risk 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
SALT LAKE CITY, April 18, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2, 2017. During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will provide an overview of Myriad’s financial performance for the fiscal third-quarter and provide a business update.
To listen to the call, interested parties in the United States may dial 888-225-2744 or +1 303-223-2690 for international callers. All callers will be asked to reference reservation number 21849837. The conference call also will be available through a live webcast and a slide presentation pertaining to the earnings call will also be available under the investor section of our website at www.myriad.com. A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers and entering reservation number 21849837.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, GeneSight, EndoPredict and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
